U.S. markets open in 6 hours 44 minutes
  • S&P Futures

    3,924.75
    +2.25 (+0.06%)
     
  • Dow Futures

    31,961.00
    +45.00 (+0.14%)
     
  • Nasdaq Futures

    13,294.50
    -7.50 (-0.06%)
     
  • Russell 2000 Futures

    2,296.20
    +11.10 (+0.49%)
     
  • Crude Oil

    63.49
    +0.27 (+0.43%)
     
  • Gold

    1,790.40
    -7.50 (-0.42%)
     
  • Silver

    27.85
    -0.00 (-0.01%)
     
  • EUR/USD

    1.2176
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.34
    -1.77 (-7.66%)
     
  • GBP/USD

    1.4124
    -0.0017 (-0.12%)
     
  • USD/JPY

    106.0400
    +0.1580 (+0.15%)
     
  • BTC-USD

    50,545.07
    +585.73 (+1.17%)
     
  • CMC Crypto 200

    1,010.52
    +15.86 (+1.59%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

HOOKIPA Pharma to Participate in Upcoming Investor Conferences in November

  • Oops!
    Something went wrong.
    Please try again later.
Hookipa Pharma Inc
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK and VIENNA, Austria, Nov. 11, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in two upcoming virtual investor conferences:

  • The SVB Leerink Oncology 1x1 Day, November 19, 2020

  • The Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020

HOOKIPA will participate in virtual one-on-one meetings during these events.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating (VaxWave®) and replicating (TheraT®), induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

In addition, HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact:

Media

Investors

Nina Waibel

Matt Beck

Senior Director - Communications

Executive Director - Investor Relations

nina.waibel@hookipapharma.com

matthew.beck@hookipapharma.com